Kidney StonesNCT00351351
Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
A study testing Cyberwand and single probe ultrasonic in people with Kidney Stones, run by Indiana Kidney Stone Institute at 7 sites in 2 countries.
Trial summary
Percutaneous nephrolithotomy (PNL), in conjunction with intracorporeal lithotripsy, allows for the rapid removal of any kidney stone regardless of size. Currently, the choice of intracorporeal lithotripters includes ultrasonic, pneumatic, and combined ultrasonic/pneumatic energy sources. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Stones
- What is being tested?
- Cyberwand and single probe ultrasonic
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 7 sitesin 2 countries
- Study dates
- Jul 2006to May 2008
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient of Methodist Urology in Indianapolis, IN
- Undergoing percutaneous nephrolithotomy for calculi greater than 2 cm
- Age 18 years or older
- Stone easily visible/measurable on kidney, ureters and bladder (KUB) or computed tomography (CT) scan preoperatively
Who cannot join
- Radiolucent stones
- Size of largest stone less than 2 cm
- Pregnancy
- Inability to give informed consent
- Multiple percutaneous access anticipated
- Active urinary tract infection
- Recent (within last 3 months) extracorporeal shock wave lithotripsy
Trial locations and contacts
7 sites in 2 countries.
7 sites in 2 countries
United States5 sites
John's Hopkins University
Baltimore, Maryland
Northwestern University Dept. of Urology
Chicago, Illinois, 60611
Duke University
Durham, North Carolina, 27710
Methodist Hospital
Indianapolis, Indiana, 46202
University of Wisconsin
Madison, Wisconsin, 53792
Canada2 sites
University of Western Ontario - St. Joseph's Hospital
London, Ontario
Vancouver Hospital
Vancouver, British Columbia
About this study
Official title: Randomized Control Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Percutaneous nephrolithotomy (PNL), in conjunction with intracorporeal lithotripsy, allows for the rapid removal of any kidney stone regardless of size. Currently, the choice of intracorporeal lithotripters includes ultrasonic, pneumatic, and combined ultrasonic/pneumatic energy sources. Recently, a novel dual probe design as been introduced by Cybersonics of Erie, Pennsylvania. This dual probe intracorporeal lithotrite is called the Cyberwand, and is composed of a fixed inner probe vibrating at an ultrasonic frequency with an outer probe vibrating at about 1,000 Hz. As this new design has the potential to revolutionize intracorporeal lithotripsy, we intend to compare this novel technology to currently available lithotripsy technology in a randomized clinical trial.
Read the detailed description
Percutaneous nephrolithotomy (PNL) is used to remove large and complex stones from the upper urinary tract. Intracorporeal lithotripsy is an integral part of PNL. Commercially available intracorporeal lithotripsy modalities include ultrasonic, pneumatic, and combined ultrasonic and pneumatic models. Each modality has its inherent advantages and disadvantages. Ultrasonic lithotrites are capable of fragmenting stones while concomitantly suctioning out fragments. Unfortunately some stones are hard enough to resist fragmentation from ultrasonic lithotripsy. Pneumatic lithotrites are able to fragment all stones regardless of hardness, but this modality is unable to suction out stone pieces at the same time fragmentation is occurring. The newest lithotrite which combines both ultrasonic and pneumatic components is capable of fragmenting any stone, but also has some inherent limitations. The handpiece of the lithotripsy device is somewhat cumbersome, the suction component can clog, and the device has overheated at the maximal settings (Kuo et al). Current intracorporeal lithotrites, while functional, can certainly be improved.
Recently, a novel dual probe design has been introduced by Cybersonics of Erie, PA. This dual probe intracorporeal lithotrite is called the Cyberwand and is composed of a fixed inner probe vibrating at an ultrasonic frequency with an outer probe vibrating at about 1,000 Hz. As this new design has the potential to revolutionalize intracorporeal lithotripsy, we intend to compare this novel technology to currently available lithotripsy technology in a randomized clinical trial.
- Conditions
- Kidney Stones
- Being tested
- Cyberwand, single probe ultrasonic
- Keywords
- Kidney Stones, Renal Calculi
- Medical subject headings
- Kidney Calculi
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CyberwandDevice
FDA approved - dual probe intracorporeal lithotrite
single probe ultrasonicDevice
FDA-approved - single probe ultrasonic
| Study group | Role | What they receive |
|---|---|---|
| A | Experimental | Cyberwand Receives: Device: Cyberwand |
| B | Active comparator | Currently available lithotripsy technology Receives: Device: single probe ultrasonic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Kidney Stone Clearance Rate
stone clearance rate calculated in mm^2/min per protocol specification
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2006 (estimated)
- Study startJul 2006
- Primary completionMay 2008
- Study completionMay 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Kidney StonesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indiana Kidney Stone Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- James E. Lingeman, MD, Principal investigator, Methodist Urology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00351351
- Sponsor's protocol ID
- 06-035
- Status last verified
- Feb 2013
- First submitted
- 11 Jul 2006
- Last updated
- 30 Mar 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Kuo RL, Paterson RF, Siqueira TM Jr, Evan AP, McAteer JA, Williams JC Jr, Lingeman JE. In vitro assessment of lithoclast ultra intracorporeal lithotripter. J Endourol. 2004 Mar;18(2):153-6. doi: 10.1089/089277904322959789.
PubMed 15072622